Loading...
AKUS logo

Akouos, Inc.NasdaqGS:AKUS Stock Report

Market Cap US$491.0m
Share Price
n/a
1Y50.3%
7D0.9%
1D1.1%
Portfolio Value
​
View

Akouos, Inc.

NasdaqGS:AKUS Stock Report

Market Cap: US$491.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Akouos (AKUS) Stock Overview

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. More details

AKUS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year


AKUS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW493,086 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
493,086 investors already sharing narratives
View all narratives

Akouos, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Akouos
Historical stock prices
Current Share PriceUS$13.29
52 Week HighUS$13.60
52 Week LowUS$2.32
Beta-0.56
1 Month Change1.22%
3 Month Change270.20%
1 Year Change50.34%
3 Year Changen/a
5 Year Changen/a
Change since IPO-39.59%

Recent News & Updates

Analysis Article • Sep 19

Is Akouos (NASDAQ:AKUS) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

Analysis Article • Sep 19

Is Akouos (NASDAQ:AKUS) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 13

Akouos stock rises 11% on FDA nod to start gene therapy trial for hearing loss

The U.S. Food and Drug Administration (FDA) cleared Akouos' (NASDAQ:AKUS) investigational new drug application (IND) seeking to start a phase 1/2 trial of gene therapy therapy AK-OTOF to treat pediatric patients with otoferlin gene (OTOF)-mediated hearing loss. The company said it plans to begin a pediatric phase 1/2 study, which includes children as young as two years of age in the dose-escalation phase (Part A), to evaluate AK-OTOF. "This first in human clinical trial for AK-OTOF is groundbreaking and highlights Akouos’s leadership in the field -- we expect this to be the first clinical trial for a genetic inner ear condition, the first in which an AAV gene therapy is administered to the inner ear, and the first for any inner ear condition to begin in a pediatric population," said Akouos Co-Founder, President and CEO Manny Simons. Based on auditory brainstem response data from nonclinical studies, a one-time administration of AK-OTOF has the potential to deliver durable restoration of auditory function, the company said in a  Sept. 13 press release. AKUS +11.14% to $3.89 premarket Sept. 13
Analysis Article • Jun 04

We Think Akouos (NASDAQ:AKUS) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Feb 19

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 28

Companies Like Akouos (NASDAQ:AKUS) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 26

Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 04

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 10

Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Analysis Article • Nov 18

Akouos (NASDAQ:AKUS) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

AKUSUS BiotechsUS Market
7D0.9%-2.0%0.1%
1Y50.3%34.9%20.3%

Return vs Industry: AKUS exceeded the US Biotechs industry which returned -10.3% over the past year.

Return vs Market: AKUS exceeded the US Market which returned -16.1% over the past year.

Price Volatility

Is AKUS's price volatile compared to industry and market?
AKUS volatility
AKUS Average Weekly Movement27.9%
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: AKUS's share price has been volatile over the past 3 months.

Volatility Over Time: AKUS's weekly volatility has increased from 20% to 28% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016103Manny Simonswww.akouos.com

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company’s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene.

Akouos, Inc. Fundamentals Summary

How do Akouos's earnings and revenue compare to its market cap?
AKUS fundamental statistics
Market capUS$491.02m
Earnings (TTM)-US$92.59m
Revenue (TTM)n/a
0.0x
P/S Ratio
-5.3x
P/E Ratio

Is AKUS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AKUS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$92.59m
Earnings-US$92.59m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.51
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did AKUS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/01 07:43
End of Day Share Price 2022/11/30 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akouos, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
null nullBTIG
Joseph PantginisH.C. Wainwright & Co.